The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Benefit of interferon β-1a on MSFC progression in secondary progressive MS
Abstract
BACKGROUND: Interferon beta-1a (IFNbeta-1a, Avonex) is efficacious in relapsing forms of MS. Studies of other IFNbeta preparations in secondary progressive MS (SPMS) yielded conflicting results. This study was undertaken to determine whether IFNbeta-1a slowed disease progression in SP-MS. METHODS: A total of 436 subjects with SPMS and Expanded Disability Status Scale (EDSS) score 3.5 to 6.5 were randomized to receive IFNbeta-1a (60 micro g) or placebo by weekly intramuscular injection for 2 years. The primary outcome measure, used for the first time in a large-scale MS trial, was baseline to month 24 change in the MS Functional Composite (MSFC), comprising quantitative tests of ambulation (Timed 25-Foot Walk), arm function (Nine-Hole Peg Test [9HPT]), and cognition (Paced Auditory Serial Addition Test [PASAT]). RESULTS: Median MSFC Z-score change was reduced 40.4% in IFNbeta-1a subjects (-0.096 vs -0.161 in placebo subjects, p = 0.033), an effect driven mainly by the 9HPT and PASAT. There was no discernible benefit on the EDSS, which in this range principally reflects walking ability. IFNbeta-1a subjects had 33% fewer relapses (p = 0.008). There was significant benefit on eight of 11 MS Quality of Life Inventory subscales. New or enlarging T2-hyperintense brain MRI lesions and gadolinium-enhancing lesions were reduced at months 12 and 24 (both p < 0.001). IFNbeta-1a was well tolerated by the majority of subjects. Neutralizing antibodies developed in 3.3% of IFNbeta-1a-treated subjects. CONCLUSIONS: IFNbeta-1a demonstrated benefit on MSFC progression, relapses, quality of life, and MRI activity in SPMS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)
Kurtzke, J. F. (1983) · Neurology · doi:10.1212/wnl.33.11.1444 · Cited by 15,011
New diagnostic criteria for multiple sclerosis: Guidelines for research protocols
Poser, C. M., Paty, D. W., Scheinberg, L., McDonald, W. I., Davis, F. A., Ebers, G. C., Johnson, K. P., Sibley, W. A., Silberberg, D. H., & Tourtellotte, W. W. (1983) · Annals of Neurology · doi:10.1002/ana.410130302 · Cited by 7,384
Defining the clinical course of multiple sclerosis: Results of an international survey
Lublin, F. D., Reingold, S. C., & National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis* (1996) · Neurology · doi:10.1212/wnl.46.4.907 · Cited by 3,686
Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosis
Jacobs, L. D., Cookfair, D. L., Rudick, R. A., Herndon, R. M., Richert, J. R., Salazar, A. M., Fischer, J. S., Goodkin, D. E., Granger, C. V., Simon, J. H., et al. (1996) · Annals of Neurology · doi:10.1002/ana.410390304 · Cited by 2,450
Self-citationJacobs, L. D., Beck, R. W., Simon, J. H., Kinkel, R. P., Brownscheidle, C. M., Murray, T. J., Simonian, N. A., Slasor, P. J., & Sandrock, A. W. (2000) · New England Journal of Medicine · doi:10.1056/nejm200009283431301 · Cited by 1,501
Self-citationDevelopment of a multiple sclerosis functional composite as a clinical trial outcome measure
Cutter, G. R. (1999) · Brain · doi:10.1093/brain/122.5.871 · Cited by 1,190
Self-citationFischer, J. S., Rudick, R. A., Cutter, G. R., Reingold, S. C., & National MS Society Clinical Outcomes Assessment Task Force (1999) · Multiple Sclerosis Journal · doi:10.1177/135245859900500409 · Cited by 993
Self-citationKappos, L. (1998) · The Lancet · doi:10.1016/s0140-6736(98)10039-9 · Cited by 936
Minimization: A new method of assigning patients to treatment and control groups
Taves, D. R. (1974) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt1974155443 · Cited by 891
Rothwell, P. M., McDowell, Z., Wong, C. K., & Dorman, P. J. (1997) · BMJ · doi:10.1136/bmj.314.7094.1580 · Cited by 548
Randomized controlled trial of interferon- beta-1a in secondary progressive MS: Clinical results
Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon-beta-1a in MS (SPECTRIMS) Study Group* (2001) · Neurology · doi:10.1212/wnl.56.11.1496 · Cited by 475
Randomized controlled trial of interferon-beta-1a in secondary progressive MS: MRI results
Li, D. K. B., Zhao, G. J., Paty, D. W., & the University of British Columbia MS/MRI Analysis Research Group and the SPECTRIMS Study Group* (2001) · Neurology · doi:10.1212/wnl.56.11.1505 · Cited by 458
Recommendations from the national multiple sclerosis society clinical outcomes assessment task force
Rudick, R., Antel, J., Confavreux, C., Cutter, G., Ellison, G., Fischer, J., Lublin, F., Miller, A., Petkau, J., Rao, S., et al. (1997) · Annals of Neurology · doi:10.1002/ana.410420318 · Cited by 371
Self-citationRecent developments in the assessment of quality of life in Multiple Sclerosis (MS)
Fischer, J. S., LaRocca, N. G., Miller, D. M., Ritvo, P. G., Andrews, H., & Paty, D. (1999) · Multiple Sclerosis Journal · doi:10.1177/135245859900500410 · Cited by 335
Self-citationIncidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis
Rudick, R. A., Simonian, N. A., Alam, J. A., Campion, M., Scaramucci, J. O., Jones, W., Coats, M. E., Goodkin, D. E., Weinstock-Guttman, B., Herndon, R. M., et al. (1998) · Neurology · doi:10.1212/wnl.50.5.1266 · Cited by 333
Self-citationMagnetic resonance studies of intramuscular interferon β–1a for relapsing multiple sclerosis
Simon, J. H., Jacobs, L. D., Campion, M., Wende, K., Simonian, N., Cookfair, D. L., Rudick, R. A., Herndon, R. M., Richert, J. R., Salazar, A. M., et al. (1998) · Annals of Neurology · doi:10.1002/ana.410430114 · Cited by 330
Self-citationGoodkin, D. E., Rudick, R. A., Medendorp, S. V., Daughtry, M. M., Schwetz, K. M., Fischer, J., & van Dyke, C. (1995) · Annals of Neurology · doi:10.1002/ana.410370108 · Cited by 304
Self-citationRudick, R. A. (1992) · Archives of Neurology · doi:10.1001/archneur.1992.00530360035014 · Cited by 246
Self-citationPhysical rehabilitation has a positive effect on disability in multiple sclerosis patients
Solari, A., Filippini, G., Gasco, P., Colla, L., Salmaggi, A., La Mantia, L., Farinotti, M., Eoli, M., & Mendozzi, L. (1999) · Neurology · doi:10.1212/wnl.52.1.57 · Cited by 241
Outcomes assessment in multiple sclerosis clinical trials: a critical analysis
Whitaker, J., McFarland, H., Rudge, P., & Reingold, S. (1995) · Multiple Sclerosis Journal · doi:10.1177/135245859500100107 · Cited by 236
Self-citationFisher, E., Rudick, R. A., Cutter, G., Baier, M., Miller, D., Weinstock-Guttman, B., Mass, M. K., Dougherty, D. S., & Simonian, N. A. (2000) · Multiple Sclerosis Journal · doi:10.1177/135245850000600602 · Cited by 185
Self-citationClinical outcomes assessment in multiple sclerosis
Rudick, R., Fischer, J., Antel, J., Confavreux, C., Cutter, G., Ellison, G., Lublin, F., Miller, A., Petkau, J., Rao, S., et al. (1996) · Annals of Neurology · doi:10.1002/ana.410400321 · Cited by 177
Self-citationUse of the Multiple Sclerosis Functional Composite as an Outcome Measure in a Phase 3 Clinical Trial
Cohen, J. A. (2001) · Archives of Neurology · doi:10.1001/archneur.58.6.961 · Cited by 177
Self-citationPerformance of the SF-36, SF-12, and RAND-36 Summary Scales in a Multiple Sclerosis Population
Nortvedt, M. W., Riise, T., Myhr, K.-M., & Nyland, H. I. (2000) · Medical Care · doi:10.1097/00005650-200010000-00006 · Cited by 175
Inpatient rehabilitation in multiple sclerosis: Do the benefits carry over into the community?
Freeman, J. A., Langdon, D. W., Hobart, J. C., & Thompson, A. J. (1999) · Neurology · doi:10.1212/wnl.52.1.50 · Cited by 157
Intrarater and interrater reliability of the MS functional composite outcome measure
Cohen, J. A., Fischer, J. S., Bolibrush, D. M., Jak, A. J., Kniker, J. E., Mertz, L., Skaramagas, T., & Cutter, G. (2000) · Neurology · doi:10.1212/wnl.54.4.802 · Cited by 149
Self-citationJanardhan, V., & Bakshi, R. (2000) · Archives of Neurology · doi:10.1001/archneur.57.10.1485 · Cited by 147
Clinical Significance of the Multiple Sclerosis Functional Composite
Miller, D. M., Rudick, R. A., Cutter, G., Baier, M. L., & Fischer, J. S. (2000) · Archives of Neurology · doi:10.1001/archneur.57.9.1319 · Cited by 145
Self-citationUse of the Multiple Sclerosis Functional Composite to predict disability in relapsing MS
Rudick, R. A., Cutter, G., Baier, M. L., Fisher, E., Dougherty, D. S., Weinstock‐Guttman, B., Mass, M. K., Miller, D., & Simonian, N. A. (2001) · Neurology · doi:10.1212/wnl.56.10.1324 · Cited by 128
Self-citationKalkers, N. F., de Groot, V., Lazeron, R. H. C., Killestein, J., Adèr, H. J., Barkhof, F., Lankhorst, G. J., & Polman, C. H. (2000) · Neurology · doi:10.1212/wnl.54.6.1233 · Cited by 98
Concurrent validity of the MS Functional Composite using MRI as a biological disease marker
Kalkers, N. F., Bergers, L. L., de Groot, V., Lazeron, R. H. C., van Walderveen, M. A. A., Uitdehaag, B. M. J., Polman, C. H., & Barkhof, F. (2001) · Neurology · doi:10.1212/wnl.56.2.215 · Cited by 82
Are quantitative functional measures more sensitive to worsening MS than traditional measures?
Schwid, S. R., Goodman, A. D., Apatoff, B. R., Coyle, P. K., Jacobs, L., Krupp, L., Miller, A., Wende, K. E., & Brownscheidle, C. M. (2000) · Neurology · doi:10.1212/wnl.55.12.1901 · Cited by 36
Self-citation(2000) · doi:10.1002/1531-8249(200012)48:6
Cited by
Compston, A., & Coles, A. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61620-7 · Cited by 4,372
Hartung, H.-P., Gonsette, R., Konig, N., Kwiecinski, H., Guseo, A., Morrissey, S. P., Krapf, H., & Zwingers, T. (2002) · The Lancet · doi:10.1016/s0140-6736(02)12023-x · Cited by 946
Evidence for a two-stage disability progression in multiple sclerosis
Leray, E., Yaouanq, J., Le Page, E., Coustans, M., Laplaud, D., Oger, J., & Edan, G. (2010) · Brain · doi:10.1093/brain/awq076 · Cited by 596
Progressive multiple sclerosis: from pathogenic mechanisms to treatment
Correale, J., Gaitán, M. I., Ysrraelit, M. C., & Fiol, M. P. (2016) · Brain · doi:10.1093/brain/aww258 · Cited by 573
Mitchell, A. J., Benito-León, J., González, J.-M. M., & Rivera-Navarro, J. (2005) · The Lancet Neurology · doi:10.1016/s1474-4422(05)70166-6 · Cited by 519
Metadata
- Authors
- Cohen, J. A., Cutter, G. R., Fischer, J. S., Goodman, A. D., Heidenreich, F. R., Kooijmans, M. F., Sandrock, A. W., Rudick, R. A., Simon, J. H., Simonian, N. A., Tsao, E. C., & Whitaker, J. N.
- Venue
- Neurology
- Published
- 2002-09-10
- Volume
- 59
- Issue
- 5
- Pages
- 679-687
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W2056736742
- Cited by
- 402
- References
- 33
- FWCI
- 12.31
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.